Basic & Clinical Medicine ›› 2022, Vol. 42 ›› Issue (8): 1279-1283.doi: 10.16352/j.issn.1001-6325.2022.08.1279
• Mini Reviews • Previous Articles Next Articles
KUANG Zhong-shen, CONG Zhu-kai, WU Chang-yi, YANG Ning, ZONG Ya-nan, GUO Xiang-yang*
Received:
2022-05-19
Revised:
2022-06-13
Online:
2022-08-05
Published:
2022-08-01
Contact:
*puthmzk@hsc.pku.edu.cn
CLC Number:
KUANG Zhong-shen, CONG Zhu-kai, WU Chang-yi, YANG Ning, ZONG Ya-nan, GUO Xiang-yang. Research progress on the role and mechanism of visfatin in sepsis-related organ injury[J]. Basic & Clinical Medicine, 2022, 42(8): 1279-1283.
[1] | Braun DA. Retrospective review of the sepsis definition after publication of sepsis-3[J]. Am J Med, 2019, 132:382-384. |
[2] | Karki R, Kanneganti TD. The ‘cytokine storm’:mole-cular mechanisms and therapeutic prospects[J]. Trends Immunol, 2021, 42:681-705. |
[3] | Black WB, Zhang LY, Mak WS, et al. Engineering a nicotinamide mononucleotide redox cofactor system for biocatalysis[J]. Nature chemical biology, 2020, 16:87-94. |
[4] | Managò A, Audrito V, Mazzola F, et al. Extracellular nicotinate phosphoribosyltransferase binds Toll like receptor 4 and mediates inflammation[J]. Nat Commun, 2019, 10:4116.doi:10.1038/s41467-019-12055-2. |
[5] | Rongvaux A, Shea RJ, Mulks MH, et al. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis[J]. Eur J Immunol, 2002, 32:3225-3234. |
[6] | Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin:a protein secreted by visceral fat that mimics the effects of insulin[J]. Science, 2005, 307:426-430. |
[7] | Nowell M, Evans L, Williams A. PBEF/NAMPT/visfatin:a promising drug target for treating rheumatoid arthritis?[J]. Future Med Chem, 2012, 4:751-769. |
[8] | Jia SH, Li Y, Parodo J, et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis[J]. J Clin Invest, 2004, 113:1318-1327. |
[9] | Bruzzone S, Fruscione F, Morando S, et al. Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE[J]. PLoS One, 2009, 4:e7897.doi:10.1371/journal.pone.0007897. |
[10] | Huffaker TB, Ekiz HA, Barba C, et al. A Stat1 bound enhancer promotes Nampt expression and function within tumor associated macrophages[J]. Nat Commun, 2021, 12:2620.doi:10.1038/s41467-021-22923-5. |
[11] | Rotllan N, Camacho M, Tondo M, et al. Therapeutic potential of emerging NAD+-increasing strategies for cardiovascular diseases[J]. Antioxidants (Basel), 2021, 10:1939.doi:10.3390/antiox10121939. |
[12] | Dakroub A, Suzanne AN, Firas Kobeissy, et al. Visfatin:An emerging adipocytokine bridging the gap in the evolution of cardiovascular diseases[J]. J Cell Physiol, 2021, 236:6282-6296. |
[13] | Bossardi Ramos R, Adam AP. Molecular mechanisms of vascular damage during lung injury[J]. Adv Exp Med Biol, 2021, 1304:95-107. |
[14] | Olszańska J, Pietraszek-Gremplewicz K, Nowak D. Melanoma progression under obesity:focus on adipokines[J]. Cancers (Basel), 2021, 13:2281.doi:10.3390/cancers13092281. |
[15] | Bermudez T,Sammani S, Hernon VR, et al. eNAMPT neutralization reduces preclinical ARDS severity via rectified NFκB and Akt/mTORC2 signaling[J].Sci Rep, 2022, 12:696.doi:10.1038/s41598-021-04444-9. |
[16] | Song J, Deng T. The Adipocyte and Adaptive Immunity[J]. Front Immunol, 2020, 11:593058.doi:10.3389/fimmu.2020.593058. |
[17] | Audrito V, Messana VG, Deaglio S. NAMPT and NAPRT: two metabolic enzymes with key roles in inflammation[J]. Front Oncol, 2020, 10:358.doi:10.3389/fonc.2020.00358.eCollection2020. |
[18] | Karampela I, Christodoulatos GS, Kandri E, et al. Circulating eNampt and resistin as a proinflammatory duet predicting independently mortality in critically ill patients with sepsis:a prospective observational study[J]. Cytokine, 2019, 119:62-70. |
[19] | Koch A, Weiskirchen R, Krusch A, et al. Visfatin serum levels predict mortality in critically Ⅲ patients[J]. Dis Markers, 2018, 2018:7315356.doi:10.1155/2018/7315356.eCollection2018. |
[20] | Meyer NJ, Gattinoni L, Calfee CS. Acute respiratory distress syndrome[J]. Lancet, 2021, 398:622-637. |
[21] | Bime C, Casanova N, Oita RC, et al. Development of a biomarker mortality risk model in acute respiratory distress syndrome[J]. Crit Care, 2019, 23:410.doi:10.1186/s13054-019-2697-x. |
[22] | Quijada H, Bermudez T, Kempf CL, et al. Endothelial eNAMPT amplifies pre-clinical acute lung injury:efficacy of an eNAMPT-neutralising monoclonal antibody[J]. Eur Respir J, 2021, 57:2002536.doi:10.1183/13993003.02536-2020.Print 2021 May. |
[23] | Liu L, Wang P, Liang C, et al. Distinct effects of Nampt inhibition on mild and severe models of lipopolysaccharide-induced myocardial impairment[J]. Int Immunopharmacol, 2013, 17:342-349. |
[24] | 李文蕾,霍洪亮. Visfatin对心肌细胞炎性因子ICAM-1,VCAM-1表达的影响[D].长春,东北师范大学, 2011, 11:1-40. |
[25] | Heo YJ, Choi SE, Lee N, et al. Visfatin exacerbates hepatic inflammation and fibrosis in a methionine-choline-deficient diet mouse model[J]. J Gastroenterol Hepatol, 2021, 36:2592-2600. |
[26] | Moschen AR, Gerner R, Schroll A, et al. A key role for Pre-B cell colony-enhancing factor in experimental hepatitis[J]. Hepatology, 2011, 54:675-686. |
[1] | LI Jinping, LIU Hanqing, YANG Quanhui. Change of cell cycle in rat spleen after severe abdominal infection [J]. Basic & Clinical Medicine, 2024, 44(6): 828-832. |
[2] | SUN Xiaoli, ZHANG Jinjin, SONG Fengying, HUANG Yongli, CHEN Lili, XING Yanchao. Tim-3/galectin-9 regulates Th1/Th2 cell balance in lipopolysaccharide-induced human lymphocytes [J]. Basic & Clinical Medicine, 2023, 43(10): 1542-1548. |
[3] | WANG Yingchen, SUN Liqun. Progress on application of dipeptidyl peptidase Ⅲ in the treatment of sepsis [J]. Basic & Clinical Medicine, 2023, 43(1): 196-199. |
[4] | XUE Jin-fang, SONG Hai-fei, CHEN Guo-bing. Research progress of programmed cell death in the occurrence and development of sepsis [J]. Basic & Clinical Medicine, 2022, 42(8): 1284-1287. |
[5] | LIN Bai-bai, QIAN Feng-hua, QIAN Yi-ming, ZHAO Lei, SUN Qi, CHU Meng-yao, SHEN Meng-wen. Research progress of sepsis complicated with capillary leakage syndrome [J]. Basic & Clinical Medicine, 2022, 42(7): 1144-1147. |
[6] | WEN Yan, LIN Jin-can, HUANG Ying-hong, XIAO Wen-biao, ZHANG Min-wei, LIN Jian-dong. Changes of BMP-2 and BMP-4 in early phase of sepsis [J]. Basic & Clinical Medicine, 2022, 42(4): 628-632. |
[7] | SHI Dan-dan, JIANG Su-fang, WANG Qian, ZHAO Peng-bo, LIU Ya. IL-6 trans-signaling inhibitor sgp130Fc suppresses inflammation and regulates immune cells in mice with sepsis [J]. Basic & Clinical Medicine, 2022, 42(12): 1895-1899. |
[8] | LI Jia-jin, LIU Jun, HE Song-yu, CHEN Hao-yun. Down-regulation of miR-27a alleviates lung injury in septic rat models [J]. Basic & Clinical Medicine, 2022, 42(11): 1704-1708. |
[9] | WANG Yu-long, TENG Wen-bin, SHAN Yue, YAO Liu-xu, HE Rui, LI Yu-hong, ZHU Sheng-mei. Effects of HIF-1α agonist or inhibitor on intestinal mucosal permeability in rats with sepsis [J]. Basic & Clinical Medicine, 2021, 41(11): 1618-1623. |
[10] | SHAO Rui-fei, YANG Yan, ZHENG Zhi-rong, ZHAO Shi-min, CHEN Guo-bing. Function of gut microbiota and “gut-lung” axis in sepsis [J]. Basic & Clinical Medicine, 2020, 40(8): 1109-1112. |
[11] | HE Rui, ZHU Ye-ke, TENG Wen-bin, SHAN Yue, YI Sheng-hua, ZHU Sheng-mei, LI Yu-hong. Glycerol may reduce intestinal mucosal barrier damage in sepsis mice through aquaporin 3 [J]. Basic & Clinical Medicine, 2020, 40(5): 655-661. |
[12] | WEN Da-lin, DU Juan, CHEN Min-jia, SUN Jian-hui, ZHANG Hua-cai, ZHANG An-qiang, DU Ding-yuan. Combined detection of C-reactive protein and procalcitonin in early prediction of patients with post-traumatic sepsis [J]. Basic & Clinical Medicine, 2020, 40(2): 178-181. |
[13] | . LXA4 reduces LPS-induced inflammatory cytokines release in obesity rats [J]. Basic & Clinical Medicine, 2018, 38(12): 1749-1752. |
[14] | Rui-lan WANG; Qiao WEI; Fu-xin KANG; Shu CAO; Guo-ping LI; Song-wei RU; Cai-hua LI. Cobra venom factor inhibited inflammatory responses in septic rats [J]. Basic & Clinical Medicine, 2008, 28(11): 1178-1182. |
Viewed | ||||||||||||||||||||||||||||||||||||||||||||||||||
Full text 159
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Abstract 228
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||